Find a lawyer
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod.
After a solid year in 2023, we assess how private capital and digital transition will shape the sector’s prospects in 2024
Higher borrowing costs and economic turbulence made for a subdued 2023, but 2024 should prove busier
2024 should see an uptick in deals across the sector but regulatory attention is never far away
Despite economic and geopolitical disruption last year, biopharma M&A remained resilient and looks set for a busy 2024
Heightened interest rates have dampened enthusiasm for M&A and raised questions on how to fund deals
2023 was a difficult year, but appetite remains among corporates with strong balance sheets and funds sitting on dry powder
The transition to battery-powered vehicles reliant on advanced tech means more consolidation
From the ongoing demands of the energy transition to geopolitical shocks and regulatory churn, we summarise key market developments from around the world
Pillar Two global minimum tax is a global game-changer
2024 promises to be a stronger year for M&A as economic stability returns and dealmakers normalise geopolitical uncertainty
A drop in venture capital activity and ongoing economic headwinds resulted in a sluggish year for deals, but 2024 shows signs of improvement
Explore all sub topics
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod.